\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
MENLO PARK, Calif. , July 12, 2022 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical-stage biotechnology company that leverages the strength of mitochondria and peptides encoded in its genome to expand potential innovative treatments targeting chronic and age-related diseases, announced the appointment of Effie Tozzo, Ph. D. as an independent director on the Company’s Board of Directors, effective July 11, 2022. Tozzo brings extensive studies and progress experience to established pharmaceutical corporations and cutting-edge biotechnology corporations.
“We are excited to add Dr. Tozzo to our Board of Directors and will leverage his wealth of experience in advancing preclinical assets to the clinic and building solid pipelines,” said David Greenwood, President of CohBar. “Effie’s extensive studies and progression delight in the willingness to provide useful information as we continue to view the mitochondrial genome as a potential source of new therapies. Your attitude will indicate the continued progress of our preclinical and clinical programs.
“I look forward to joining CohBar’s board of directors at this exciting time as the company strives to bring a candidate for the time being to the clinic,” said Dr. Tozzo. “CohBar’s Mito platform and its new drug discovery technique have prospective applications in a wide variety of cure indications. I am pleased to contribute to the advancement of the company’s portfolio to gain benefits for patients who want new treatments to treat life-threatening diseases such as IPF.
Dr. Tozzo is most recently Chief Scientific Officer of Avilar Therapeutics, a biotechnology company that creates a broad and varied portfolio of extracellular protein degraders as first-class drugs for the treatment of serious diseases. As a leader in drug discovery, translational sciences, and medicine, Dr. Tozzo has over 26 years of experience in leadership roles in biotechnology/start-ups and giant pharmaceutical organizations. He initiated complex discovery systems in the clinic through the construction of wells and led groups in preclinical biology, chemistry, pharmacology, DMPK, protection and biomarkers. studies in various indications of diseases.
For the 8 years, Dr. Tozzo has worked at Cellarity (a pioneering leader) as Senior Vice President of Drug Development and Director of R
Earlier in her career, Dr. Tozzo held leadership positions at Merck, Roche, BMS, Millennium, Chiron, and ErgoScience. She earned her Ph. D. in Molecular and Cellular Endocrinology from XI University in Paris, France, completed her postdoctoral education in the Division of Endocrinology at Beth Israel/Harvard Medical School in Boston, and is the author of more than 40 peer-reviewed publications and patents.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company that harnesses the strength of mitochondria and peptides encoded in its genome to expand potential innovative treatments targeting chronic and age-related diseases with few or no remedy options. CohBar has gained a leading position in the exploration of the mitochondrial genome and its usefulness for the progression of new treatments, adding world-renowned expertise in mitochondrial biology, a broad box of intellectual properties, leaders of key ideas and disciplined processes of drug discovery and progression. CohBar uses its Mito platform to identify and expand modified versions of herbal peptides called analogues to treat a variety of serious diseases, with a focus on diseases involving inflammation and fibrosis.
For more information about the company, visit www. cohbar. com and contact us on LinkedIn.
Forward-Looking Statements
This press release comprises forward-looking statements that are not facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based solely on our existing beliefs, expectations and assumptions about the long term of our business. our long-term plans and strategies, projections, expected events and other long-term conditions. In some cases, you may identify those statements by forward-looking words such as “believe”, “possibly”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “you may also simply “. Array” should”, “would”, “project”, “plan”, “expect”, “meta”, “seek”, “long term”, “probable” or the negative or plural of those similar words or expressions. Examples of such forward-looking statements include, but are not limited to, statements regarding the timing and expected effects of clinical studies and trials for our product candidates; expectations related to the expansion of treatments evolved from mitochondrial peptides designed as a vital long-term component of pharmaceuticals; and statements regarding the expected and prospective healing sites of our mitochondrial peptide analogs and other prospective treatments. You are cautioned that such statements are not promises of long-term functionality and that actual effects or progressions may differ materially from those set forth in such forward-looking statements. Factors that may also cause actual effects to differ materially from those forward-looking statements include: our ability to effectively advance drug discovery and progress programs, add suspension or termination of ongoing clinical trials, and timing of announcements and updates related to our clinical trials and similar knowledge; our conceivable ability to mitigate the prevalence and/or longevity of injection site reactions, or the option of other progressions affecting visual ability of CB4211 or CB5138-3 as a clinical candidate or prospective advertisement; effects that differ from prior knowledge effects, adding less favorable effects that might not help further clinical progression; our ability to raise additional capital as necessary to continue our operations; our ability to recruit and retain key clinical and management personnel; the threat that our intellectual assets may not be adequately protected; our ability to identify and maintain alliances with corporate and industry partners; and threats similar to the impact on our business of the COVID-19 pandemic or similar public health crisis. Additional assumptions, threats and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website and at www. sec. . gov or www. sedar. com.
You are cautioned that these statements are not promises of long-term functionality and that our actual effects may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other data contained in this press release are made as of the date hereof and CohBar assumes no legal responsibility to publicly update or revise any forward-looking statements or data, whether as a result of new data, long-term events or otherwise, as required by applicable securities laws. offer to sell or the solicitation of an offer to buy securities.
Contacts: Jordyn TaraziDirector of Investor RelationsCohBar, Inc. (650) 445-4441Jordyn. tarazi@cohbar. com